

References

I-119

1. Moughalian SS, Kish JK, Zhang J, Liassou D, et al. Effectiveness of Eribulin in Metastatic Breast Cancer: 10 Years of Real-World Clinical Experience in the United States. *Advances in Therapy*. 2021;38(5):2213-2225.
2. Eslamian G, Wilson C, Young RJ. Efficacy of eribulin in breast cancer: a short report on the emerging new data. *Oncotargets and Therapy*. 2017;773-779.
3. Asano M, Makoto J, Towle J, et al. "Broad-spectrum preclinical antitumor activity of eribulin (Halaven®): combination with anticancer agents of differing mechanisms." *Anticancer res*. 2018. 38(6):3375-3385.
4. Fleeman N, Bagust A, Duarte R, et al. Eribulin for treating advanced or metastatic breast cancer after one chemotherapy regimen: An evidence review group perspective of a NICE single technology appraisal. *Pharmacoecon Open*. 2019.1:1-0.
5. Chang AY, Ying XX. Brain metastases from breast cancer and response to treatment with eribulin: A case series. *Breast Cancer*. 2015;9:19-24.
6. Eribulin mesylate In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated 10/31/2011.
7. Clinical PharmacologyTM Compendium. 2023. Tampa FL: Gold Standard, Inc. Eribulin mesylate.
8. Micromedex DrugDex Compendium. 2023. ®. 2022. Eribulin mesylate.
9. National Comprehensive Cancer Network (NCCN). Eribulin mesylate. NCCN Drugs and Biologics Compendium®. 2023.
10. Halaven (eribulin mesylate), for injection [package insert]. Eisai, Inc. Woodcliff Lakes, NJ. Revised 09/2022.